David F. McDermott
Beth Israel Deaconess Medical Center(US)Harvard University(US)Anne Arundel Medical Center(US)Hadassah Medical Center(IL)Dana-Farber/Harvard Cancer Center(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, CAR-T cell therapy research, Cancer Genomics and Diagnostics, Renal and related cancers
Most-Cited Works
- → Improved Survival with Ipilimumab in Patients with Metastatic Melanoma(2010)15,035 cited
- → Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer(2012)12,527 cited
- → Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients(2014)5,215 cited
- → Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline(2018)3,616 cited
- → Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma(2015)2,746 cited
- → Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab(2014)2,197 cited